# Sustained Higher Levels of Plasma hsa-miR-17-5p Expression During Gestational Diabetes Mellitus and Postpartum

**Authors:** Arathi Pillai, Sibin M Kandi, Nidhi Tripathy, Deeptika Agarwal, Indrani Mukhopadhyay, Bhasker Mukherjee, Y Vashum

PMC · DOI: 10.3390/epigenomes9040037 · Epigenomes · 2025-09-24

## TL;DR

This study found that certain miRNAs, especially hsa-miR-17-5p, remain elevated in women with gestational diabetes even after giving birth.

## Contribution

The study identifies sustained elevated levels of hsa-miR-17-5p in GDM patients postpartum, suggesting its potential as a biomarker.

## Key findings

- hsa-miR-16-5p, hsa-miR-17-5p, and hsa-miR-20a-5p are significantly higher in GDM patients compared to normoglycemic controls.
- hsa-miR-17-5p remains elevated in GDM patients even after they return to normoglycemia postpartum.
- hsa-miR-16-5p levels are higher in postpartum GDM patients compared to normoglycemic controls.

## Abstract

Background: The role of circulatory miRNAs in gestational diabetes mellitus (GDM) was explored extensively in previous studies. However, there was limited literature on longitudinal studies exploring the changes in miRNA expression during pregnancy and postpartum to understand the changes in their expression levels in GDM patients. Methods: Blood samples from thirty GDM subjects and twenty normoglycemic pregnant women (NGT) were collected between 24 and 28 weeks of their pregnancy, and follow-up samples from the same subjects were collected till 12 weeks postpartum (FGDM and FNGT, respectively). Three candidate miRNAs, hsa-miR-16-5p, hsa-miR-17-5p, and hsa-miR-20a-5p, were quantified from their plasma samples using RT-qPCR. Comparative analysis of these miRNA expression levels was made between different groups. Results: hsa-miR-16-5p, hsa-miR-17-5p, and hsa-miR-20a-5p expression were significantly higher in GDM patients when compared to NGT subjects. Interestingly, hsa-miR-17-5p has shown consistent upregulation in FGDM even after these patients turned normoglycemic. Additionally, hsa-miR-16-5p was found to be higher in FGDM patients compared to FNGT subjects. Conclusions: The present study corroborated the finding of differential expression of hsa-miR-16-5p, hsa-miR-17-5p, and hsa-miR-20a-5p in GDM. It also marked the importance of monitoring the levels of hsa-miR-17-5p and hsa-miR-16-5p during pregnancy and postpartum in GDM patients.

## Linked entities

- **Diseases:** gestational diabetes mellitus (MONDO:0005406)

## Full-text entities

- **Diseases:** GDM (MESH:D016640)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12551101/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12551101/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12551101/full.md

---
Source: https://tomesphere.com/paper/PMC12551101